Follow the Money: Lexicon Pharmaceuticals, Inc.
Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.
Lexicon Pharmaceuticals, Inc. is a U.S. public pharmaceutical company that develops treatments using a gene knockout technology to identify human gene targets in metabolism, cardiology, immunology, gastroenterology, and ophthalmology. As reported in the December 4, 2014 issue of the PharmSource Lead Sheet, Lexicon raised $149.9 million in a private equity placement.
- Lexicon was incorporated in Delaware in July 1995 and began operations in September 1995.
- Corporate Headquarters: The Woodlands, Texas – approximately 260,000 square feet of office and laboratory space.
- Facility: Princeton, New Jersey – approximately 42,000 square feet of office and laboratory space.
- As of February 27, 2014, Lexicon had 149 employees.
- Lexicon plans to use the proceeds for clinical development of its drug candidates, other nonclinical R&D, and general corporate purposes.
- The company relies on CROs and other third party contractors to carry out drug development activities, including testing and clinical trials of drug candidates.
- Lexicon does not have manufacturing capabilities and relies on third parties to produce materials for preclinical studies, clinical trials, and commercial sales.
- Lexicon has no sales, marketing or distribution capabilities.
- In December 2002, Lexicon entered into an alliance with Genentech to discover therapeutic proteins and antibody targets.
- December 2003, Lexicon entered into an alliance with Bristol-Myers Squibb (BMS) to discover, develop, and commercialize small molecule drugs in neuroscience. BMS will have the first option to develop and commercialize candidates resulting from the collaboration.
- In July 2004, Lexicon entered into an alliance with Takeda to discover novel treatments for high blood pressure.1
- In October 2014, Lexicon entered into a licensing agreement with Ipsen to commercialize telotristat etiprate outside the US, Canada, and Japan, for the treatment of carcinoid syndrome.2
|Product Candidate||Indication||Dosage Form||Status||Next Anticipated Step|
|Ulcerative Colitis||Oral||Phase II||TBA|
|LX1033||Irritable Bowel Syndrome (IBS-d)||Oral||Phase II||TBA|
|LX2931||Rheumatoid Arthritis||Oral||Phase II||TBA|
|LX4211||Type I Diabetes||Tablet||Phase II||Plans to initiate a Phase III trial in early 2015.|
|LX4211||Type II Diabetes||Tablet||Phase II||TBA|
|Carcinoid Syndrome||Oral||Phase III||Plans to complete enrollment in Phase III trial by the end of 2014.|
|(In $ thousands)||2013||2012|
|General & Administrative Expenditures||17,121||17,043|
|Total Operating Expenses||104,593||109,504|
|Lexicon Pharmaceuticals, Inc.||Key Officers|
|8800 Technology Forest Place||Lonnel Coats, President & CEO|
|The Woodlands, TX 77381, USA||Jeffrey L. Wade, CFO & EVP|
|Phone: 281-863-3000||Pablo Lapuerta, MD, CMO & EVP, Safety & Pharmacovigilance|
|Fax: 281-863-8088||Alan J. Main, PhD, EVP, Pharmaceutical Research|
|Web: www.lexpharma.com||Brian P. Zambrowicz, PhD, CSO & EVP|
Read more postings by Ryan